Andrea Cox is a Professor of Medicine and Oncology at The Johns Hopkins University School of Medicine in Baltimore. She earned her Ph.D. studying T cell immunology at The University of Virginia. She subsequently completed an M.D. and then Internal Medicine and Infectious Disease training at Johns Hopkins. As a member of the Viral Hepatitis Center in the Division of Infectious Diseases, she specializes in the treatment of patients with hepatitis virus infections and HIV. Her laboratory investigates human immune responses to hepatitis C virus (HCV), hepatitis B virus (HBV), SARS-CoV-2, and other viruses and in HCV vaccine development. She is the PI of a U19 investigating mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine and co- leads the Johns Hopkins SARS-CoV-2 Pathogenesis and Immunity Center. She was the principal investigator on the first prophylactic HCV vaccine trial implemented in an at-risk population and was the lead immunologist on an ACTG trial of HBV vaccines in people living with HIV. She is a Fellow of the Infectious Disease Society of America and a member of the American Society for Clinical Investigation and Alpha Omega Alpha Honor Society.